Lixte Biotechnology Holdings- Warrants (01/01/2025) Debt to Equity

The latest debt-to-equity ratio for LIXTW is 0.05. That is below the Healthcare sector average of 0.28. Investors often review this figure alongside Lixte Biotechnology Holdings- Warrants (01/01/2025)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, LIXTW currently prints 0.05 for debt-to-equity ratio, while the sector average sits near 0.28. That is roughly 83.3% below the sector mean. Large gaps often invite a closer look at Lixte Biotechnology Holdings- Warrants (01/01/2025)'s growth, margins, and balance sheet.

A debt-to-equity ratio of 0.05 for Lixte Biotechnology Holdings- Warrants (01/01/2025) is not 'good' or 'bad' on its own. Compare it with the peer average (0.28) and with LIXTW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting LIXTW's debt-to-equity ratio (0.05), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lixte Biotechnology Holdings- Warrants (01/01/2025)'s debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.